No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease
2012 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease
Hillmann, A.; Hahn, S.; Schilling, S.; Hoffmann, T.; Demuth, H.-U.; Bulic, B. & Schneider-Axmann, T. et al. (2012)
Neurobiology of Aging, 33(4) art. 833.e39. DOI: https://doi.org/10.1016/j.neurobiolaging.2011.08.006
Documents & Media
Details
- Authors
- Hillmann, Antje; Hahn, Stefanie; Schilling, Stephan; Hoffmann, Torsten; Demuth, Hans-Ulrich; Bulic, Bruno; Schneider-Axmann, Thomas; Bayer, Thomas A.; Weggen, Sascha; Wirths, Oliver
- Abstract
- Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that has been reported to reduce the risk of developing Alzheimer's disease (AD). Its preventive effects in AD are likely pleiotropic as ibuprofen displays both anti-inflammatory activity by inhibition of cyclooxygenases and anti-amyloidogenic activity by modulation of gamma-secretase. In order to study the anti-inflammatory properties of ibuprofen independent of its anti-amyloidogenic activity, we performed a long-term treatment study with ibuprofen in 5XFAD mice expressing a presenilin-1 mutation that renders this AD model resistant to gamma-secretase modulation. As expected, ibuprofen treatment for 3 months resulted in a reduction of the inflammatory reaction in the 5XFAD mouse model. Importantly, an unchanged amyloid beta (A beta) plaque load, an increase in soluble A beta 42 levels, and an aggravation of some behavioral parameters were noted, raising the question whether suppression of inflammation by nonsteroidal anti-inflammatory drug is beneficial in AD. (C) 2012 Elsevier Inc. All rights reserved.
- Issue Date
- 2012
- Status
- published
- Publisher
- Elsevier Science Inc
- Journal
- Neurobiology of Aging
- ISSN
- 0197-4580